Nanoscope Therapeutics to Detail MOGENRY Progress at Mesa 2026

Dr. Mohanty is scheduled to speak on Tuesday, October 6, at 11:15 AM at the Arizona Biltmore Hotel. His update will focus on the company’s lead asset, MOGENRY (sonpiretigene isteparvovec), a one-time optogenetic therapy currently undergoing FDA review for the treatment of inherited retinal dystrophies. The presentation will address the status of the company’s Biologics License Application and broader efforts toward global regulatory approval.

Nanoscope’s proprietary technology aims to restore vision by delivering light-sensitive opsin genes to bipolar retinal cells, effectively bypassing damaged photoreceptors. Following positive data from the RESTORE Phase 2b/3 trial, the company is positioning MOGENRY as a potential standard of care that avoids the need for genetic testing or complex surgery. Beyond the BLA review, Nanoscope is expanding its clinical pipeline, with a Phase 3 trial for Stargardt disease and a Phase 2 program for geographic atrophy both slated for 2026.